| Cat. No. |
CRP08120 |
| Product Overview |
Recombinant Streptokinase
produced in E.coli is a single non-glycosylated polypeptide chain
containing 414 amino acids and having a molecular mass of
approximately 47 kDa. |
| Description |
Streptokinase is an extracellular
metallo-enzyme produced by beta-haemolytic streptococcus and is used
as an effective and cheap clot-dissolving medication in some cases
of myocardial infarction (heart attack) and pulmonary embolism. It
belongs to a group of medications known as fibrinolytics, and works
by activating plasminogen through cleavage to produce plasmin. The
half life of streptokinase is 6 hours. |
|
Synonyms |
Streptococci streptokinase |
|
Formula |
C2100H3278N566O669S4 |
| CAS number |
9002-01-1 |
| Purity |
>95% by SDS-PAGE and HPLC
analyses. |
| Formulation |
Lyophilized from a 0.2mm filtered
concentrated (1mg/ml) solution in PBS, pH 7.4. |
| Specific Activity |
Fully biologically active when
compared to standard. The specific biological activity measured by
the ability of fibrin lysis in agarose plate was found to be
80,000U/mg. |
| Endotoxin |
Less than 1EU/mg of rSK as
determined by LAL method. |
| Reconstitution |
We recommend that this vial be
briefly centrifuged prior to opening to bring the contents to the
bottom. Reconstitute in sterile distilled water or aqueous buffer
containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. Stock
solutions should be apportioned into working aliquots and stored at
<-20°C. Further dilutions should be made in appropriate buffered
solutions. |
| Storage |
This lyophilized preparation is
stable for several weeks at 2-8°C, but should be kept at -20°C for
long term storage, preferably desiccated. Upon reconstitution, the
preparation is stable for up to one week at 2-8°C. For maximal
stability, apportion the reconstituted preparation into working
aliquots and store at -20°C to -70°C. Avoid repeated freeze/thaw
cycles. |
| Mechanism of action |
Plasmin is produced in the
blood
to break down the major constituent of blood clots
fibrin,
therefore dissolving clots once they have fulfilled their purpose in
stopping bleeding. Extra production of plasmin caused by
streptokinase breaks down unwanted blood clots, for example, in the
lungs
(pulmonary embolism). Streptokinase forms a complex in the plasma
with plasminogen to form an activator complex. This complex then
forms plasmin from unbound plasminogen. |